Although the mechanisms involved remain to be defined, the activation of PLCγ1 as assessed by immunohistochemistry is a strong prognostic factor that can discriminate between high-risk and low-risk patients with hormone-receptor-positive early breast cancers. This evidence concerns the gene NR4A1 and breast carcinoma.